Research
Neural
Concurrent exposure to liraglutide and a GIPRA is hypothesized to produce fewer GI adverse effects than exposure to liraglutide alone.
This suggests a potential strategy for reducing side effects in patients using liraglutide.
StrongConditionalmedium confidence
We hypothesize that concurrent exposure to liraglutide and a GIPRA would produce fewer GI AEs than exposure to liraglutide alone.
Why this rating
Based on the randomized, placebo-controlled study design.
Source
A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
Filip K. Knop et al. · Diabetes Obesity and Metabolism · 2024
rct · n=34Cited 35×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →